UGT1A7 haplotype is associated with an increased risk of hepatocellular carcinoma in hepatitis B carriers
about
Polymorphic expression of UDP-glucuronosyltransferase UGTlA gene in human colorectal cancerHepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors.Phospholipase C-related but catalytically inactive protein is required for insulin-induced cell surface expression of gamma-aminobutyric acid type A receptors.Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinaseFrontier of epilepsy research - mTOR signaling pathway.Thiazolidinedione-based PI3Kα inhibitors: an analysis of biochemical and virtual screening methods.Sevoflurane and isoflurane inhibit KCl-induced Class II phosphoinositide 3-kinase α subunit mediated vasoconstriction in rat aorta.ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system.Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway.Evaluation of the association studies of single nucleotide polymorphisms and hepatocellular carcinoma: a systematic review.Hepatocellular carcinoma: towards personalized medicine.Genetic polymorphisms of human UDP-glucuronosyltransferase (UGT) genes and cancer risk.In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA.Cisplatin associated with LY294002 increases cytotoxicity and induces changes in transcript profiles of glioblastoma cells.Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL.Andrographolide sensitizes cisplatin-induced apoptosis via suppression of autophagosome-lysosome fusion in human cancer cells.Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells.Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells.UGT1A polymorphisms as genetic biomarkers for hepatocellular carcinoma risk in Caucasian population.Unusual gastrointestinal and cutaneous toxicities by bleomycin, etoposide, and cisplatin: a case report with pharmacogenetic analysis to personalize treatment.Genetic polymorphisms in human UDP-glucuronosyltransferases 1A7 and the risk of gastrointestinal carcinomas: A systematic review and network meta-analysis.Enhanced proliferation of bone marrow mesenchymal stem cells by co-culture with TM4 mouse Sertoli cells: involvement of the EGF/PI3K/AKT pathway.Genetic polymorphisms of UGT1A7 and cancer risk: evidence from 21 case-control studies.Extensive analysis of signaling pathway molecules in breast cancer: association with clinicopathological characteristics.ZSTK474, a novel PI3K inhibitor, modulates human CD14+ monocyte-derived dendritic cell functions and suppresses experimental autoimmune encephalomyelitis.Fatty acid synthase regulates proliferation and migration of colorectal cancer cells via HER2-PI3K/Akt signaling pathway.Inhibitory effects of ZSTK474, a phosphatidylinositol 3-kinase inhibitor, on adjuvant-induced arthritis in rats.Plasma lipid biomarker signatures in squamous carcinoma and adenocarcinoma lung cancer patients
P2860
Q28487071-67E92D0A-471A-46FE-BB28-D3F9BF4CC584Q33543795-1D9187C1-F4A0-4B7D-AAB1-2B5F753B800EQ33717631-FBA22C2F-D77C-4FD9-93DF-D49060FBF915Q33796255-636E3701-821D-472D-BC52-7C47A7423116Q35014198-F338E501-E02A-4B93-A1E6-376B724C4B50Q35276540-B018D2B2-6B5C-4B38-BBDF-D02DE71ABA34Q36107455-D2DCCC97-C027-4A69-917F-66D70F6767CDQ37728043-F91D048E-A526-41AC-8C4D-FF60F93C0595Q37775890-94565F3F-5D56-4343-A4AD-835CB90922AAQ37829364-736095F5-A573-487F-8EFF-136541DFB6D2Q37984653-D6FFB028-B334-4CCB-87D3-3B1DD8C24CE6Q38717288-92DEDBD5-EC04-40BD-83B9-CDED78776B07Q38963261-24A89909-DF5D-4257-9516-BDEDA7EC1012Q39064313-5A603216-8B31-4B47-8D18-3A938820DBC0Q39108160-3F3A9764-5249-4933-BCF9-19AACD1ADB8EQ39402233-CB435CC6-D801-405E-880B-F0F43860AC48Q39539512-AE7A28EF-2E31-4048-B9FD-E69B748454ABQ39601528-CBC6235E-D272-46B2-9AB1-69460751343DQ40291987-A857FDAD-1971-4EEF-8160-99F56FF905B9Q42338467-C140F813-B77D-49C3-8D25-B282D89574DDQ42371640-B122D3C3-A040-4DB2-98FD-02B3B7A22838Q53056699-9D4FB903-92C6-4B15-B78C-79BC826790D4Q53091314-6F92749E-A10F-4E98-95D7-CA75B87CBFE5Q54315683-0E132DE5-A259-4618-B53C-6A5978C97DD1Q54351297-BA6FE8C3-01BB-477B-8C48-4DD82511DCB8Q54492986-6E960FC6-8D9A-41E0-8F03-3A268F9C8223Q54528619-2D9F9CEE-2D9B-478A-B0DD-2B924C76E328Q57924377-729CB9C7-0B09-45D8-810E-67BC5EDDE6B7
P2860
UGT1A7 haplotype is associated with an increased risk of hepatocellular carcinoma in hepatitis B carriers
description
im Februar 2008 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 February 2008
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 2008
@uk
name
UGT1A7 haplotype is associated ...... cinoma in hepatitis B carriers
@en
UGT1A7 haplotype is associated ...... cinoma in hepatitis B carriers
@nl
type
label
UGT1A7 haplotype is associated ...... cinoma in hepatitis B carriers
@en
UGT1A7 haplotype is associated ...... cinoma in hepatitis B carriers
@nl
prefLabel
UGT1A7 haplotype is associated ...... cinoma in hepatitis B carriers
@en
UGT1A7 haplotype is associated ...... cinoma in hepatitis B carriers
@nl
P2093
P2860
P1433
P1476
UGT1A7 haplotype is associated ...... cinoma in hepatitis B carriers
@en
P2093
Byung Chul Yoo
Jong-Won Kim
Sun-Young Kong
P2860
P304
P356
10.1111/J.1349-7006.2007.00693.X
P577
2008-02-01T00:00:00Z